The novel curcumin analogue AKT-100 targets mutant p53 in gynecologic cancer cells
Williams, G. L.; Smith, L. E.; Padilla, J. L.; Goss, A. S.; Belmares-Ortega, D.; Wu, X.; Daw, J. N.; Mitra, S.; Jagtap, P.; Choe, J.-y.; Leslie, K. K.
Show abstract
Loss of the normal tumor suppressive functions of p53, the "guardian of the genome," is common in advanced cancers. Mutations in TP53 occur in various ways which can result in p53 null tumor cells as well as in tumor cells highly expressing missense, gain of oncogenic function p53 proteins. Gain of function p53 proteins not only lose wild type p53 pro-apoptotic and DNA repair functions, but gain novel oncogenic functions. We hypothesize that directly targeting missense mutant p53 instead of downstream pathways has substantial advantages. Analogues of curcumin have been reported to bind mutant p53 to accomplish this goal. In this report, we developed a series of novel molecules derived from the curcumin backbone. We identified a particularly active curcumin analogue, AKT-100, and demonstrate binding to mutant p53 proteins to reinstate p53 wild type functionality. This agent exhibits impressive cell killing in multiple ovarian and serous endometrial cancer cells at concentrations ranging from 100-300 nM. AKT-100 is also synergistic with the PARP inhibitor olaparib and with chemotherapy by inhibiting alternative DNA repair mechanisms associated with resistance to standard therapies. RNA sequencing confirms that AKT-100 reactivates wild type p53-driven expression of genes associated with normal cell cycle regulation (induction of CDKN1A encoding p21 and GADD45A), apoptosis (induction of PMAIP1 encoding Noxa and DR5 encoding Death Receptor 5), and inhibits DNA replication and repair in cancer cells. Thus, p53 reactivators under development, such as AKT-100, hold promise as novel therapeutic agents to directly target missense mutant, gain of oncogenic function p53. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=111 SRC="FIGDIR/small/680794v2_ufig1.gif" ALT="Figure 1"> View larger version (19K): org.highwire.dtl.DTLVardef@19a8573org.highwire.dtl.DTLVardef@1af5868org.highwire.dtl.DTLVardef@d55348org.highwire.dtl.DTLVardef@14eb711_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death 94%
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 93%
- Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX 93%
Similar papers in this journal
- The Unique Pt(II)-Induced Nucleolar Stress Response and its Deviation from DNA Damage Response Pathways 95%
- Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma 94%
- Symmetrically substituted dichlorophenes inhibit N-acyl-phosphatidylethanolamine phospholipase D 94%
Similar papers in this journal
- A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53 97%
- Water-soluble 4-(dimethylaminomethyl)heliomycin exerts greater antitumor effects than parental heliomycin by targeting the tNOX-SIRT1 axis and apoptosis in oral cancer cells 96%
- Synthesis and Biological Assessment of Chalcone and Pyrazoline Derivatives as novel inhibitor for ELF3-MED23 Interaction 95%
Similar papers in this journal
- A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment. 95%
- Altering mammalian transcription networking with ADAADi: An inhibitor of ATP-dependent chromatin remodeling 94%
- A Homogeneous SIRPα-CD47 Cell-Based, Ligand-Binding Assay: Utility for Small Molecule Drug Development in Immuno-oncology. 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.